Stocks and Investing
Stocks and Investing
Fri, February 23, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Bradley Canino Reiterated (CCCC) at Strong Buy with Increased Target to $13 on, Feb 23rd, 2024
Bradley Canino of Stifel, Reiterated "C4 Therapeutics, Inc." (CCCC) at Strong Buy with Increased Target from $12 to $13 on, Feb 23rd, 2024.
Bradley has made no other calls on CCCC in the last 4 months.
There are 4 other peers that have a rating on CCCC. Out of the 4 peers that are also analyzing CCCC, 2 agree with Bradley's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Eric Joseph of "JP Morgan" Upgraded from Sell to Hold and Held Target at $6 on, Monday, January 29th, 2024
- Terence Flynn of "Morgan Stanley" Upgraded from Sell to Hold and Decreased Target to $1 on, Monday, November 6th, 2023
These are the ratings of the 2 analyists that currently disagree with Bradley
- Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $16 on, Friday, November 3rd, 2023
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $7 on, Thursday, November 2nd, 2023
Contributing Sources